DoW Vision, Clinical Trial Award | HT942526VRPCTA

FY26 DoW Vision Research Program (VRP) Clinical Trial Award (CTA) - FAQs

1) What is the FY26 DoW VRP Clinical Trial Award (CTA)?

The FY26 Department of Warfighter (DoW) Vision Research Program (VRP) Clinical Trial Award (CTA) is a US Army Medical Research Acquisition Activity (USAMRAA) funding opportunity intended to support the rapid start and execution of clinical trials aimed at improving treatment or management of service-connected eye injuries and visual dysfunction.

2) What is the main goal of this funding opportunity?

The main goal is near-term, real-world clinical impact. The program is looking for clinical trials that are ready to run and could plausibly change practice, improve outcomes, or advance care options for Service Members and Veterans affected by ocular trauma or visual dysfunction.

3) Is this opportunity meant for early-stage discovery or exploratory research?

No. The stated emphasis is not on early discovery work. The focus is on well-justified clinical trials with practical, near-term relevance and execution readiness.

4) Do proposed trials have to align with specific program priorities?

Yes. Proposed trials must clearly align with at least one of the FY26 VRP Focus Areas.

5) What kind of projects is the program looking for?

The program is looking for studies that are "ready-to-run" clinical trials with a credible plan to start quickly, enroll participants, operate the trial effectively, and generate results that can be acted on.

6) What is meant by “regulatory readiness” for this award?

Regulatory readiness refers to having the necessary regulatory authorization pathway in place when the intervention requires it (for example, an Investigational New Drug (IND) application, an Investigational Device Exemption (IDE), or comparable authorization). The opportunity expects a concrete and credible approach to meeting regulatory requirements.

7) When is an IND, IDE, or comparable authorization required?

An IND, IDE, or comparable authorization is required when it is legally necessary to test the proposed product/intervention in humans. The opportunity description highlights this as a central requirement when applicable.

8) If my trial requires an IND/IDE (or equivalent), what must be done by the application deadline?

If the clinical trial requires an IND/IDE (or equivalent), it must already be submitted to the appropriate regulatory agency by the application deadline.

9) Is submission of the IND/IDE enough to remain eligible for funding?

No. Beyond submission, the applicant must provide documentation showing communication from the regulatory agency that the authorization is active or that it is safe to proceed. Without this documentation, the application will not be considered for funding.

10) When is the regulatory documentation due?

The documentation showing that the authorization is active or that it is safe to proceed is due by March 1, 2027.

11) What happens if the March 1, 2027 regulatory documentation is not provided?

The application will not be considered for funding if the required documentation is not provided by March 1, 2027.

12) Does the opportunity provide guidance on building a regulatory plan?

Yes. The materials reference a specific resource: Attachment 7, Regulatory Strategy, indicating that applicants are expected to present a concrete regulatory pathway rather than an aspirational plan.

13) How will applications be reviewed?

Applications are evaluated through two stages: peer review (scored criteria focused on clinical impact and execution rigor) and programmatic review (portfolio fit and relevance to military health priorities).

14) What does peer review focus on?

Peer review focuses on whether the clinical trial is likely to matter clinically and whether the plan is rigorous and executable, including practical trial operations and readiness.

15) What are the key scored peer review elements mentioned?

The opportunity description highlights scored elements that include clinical impact; overall research strategy and feasibility; trial operations such as recruitment, accrual, and retention; regulatory strategy and transition plan; statistical plan and data analysis approach; ethical considerations; and the strength of the research team (including communication and coordination).

16) Why are recruitment, accrual, and retention called out specifically?

The award expects applicants to show they can actually enroll and keep participants in the trial and run the trial successfully, not just justify the scientific idea.

17) What is meant by a “transition plan” in this announcement?

The transition plan is described as how the project moves from trial results toward broader adoption, next-phase trials, or implementation. Reviewers score this element as part of peer review.

18) How important are the statistical plan and data analysis approach?

They are explicitly listed among the scored peer review elements, reflecting the expectation that the trial will be analyzed appropriately and yield actionable results.

19) What role do ethical considerations play in review?

Ethical considerations are included among the scored peer review elements, indicating that reviewers will evaluate how the study addresses ethical issues relevant to clinical trials.

20) How is the research team evaluated?

The strength of the research team is scored, including how personnel will communicate and coordinate, which emphasizes execution capability and operational readiness.

21) What is programmatic review and how is it different from peer review?

Programmatic review considers whether the proposal matches the intent of the Clinical Trial Award, how it fits within and strengthens the VRP portfolio, and its relative impact and relevance to military health. A proposal can score well in peer review but still needs to align with DoD vision injury priorities and portfolio needs.

22) Can a strong peer review score guarantee funding?

No. The description explains that programmatic review also considers intent, portfolio fit, and military health relevance, meaning a well-scored proposal must still resonate with VRP and DoD priorities.

23) Who is the target beneficiary population for the work?

The work is aimed at improving care for individuals affected by service-connected ocular trauma or visual dysfunction, with explicit emphasis on Service Members and Veterans.

24) What is the grant type and assistance listing information provided?

This is described as a discretionary grant with CFDA 12.420.

25) Who is eligible to apply?

The listing indicates unrestricted eligibility, meaning applicant type is not narrowly limited in the provided information.

26) What is the funding opportunity number?

The funding opportunity number is HT942526VRPCTA.

27) What is the application closing date?

The closing date provided is November 12, 2026.

28) How many awards are expected?

The posting indicates an expectation of one award.

29) Is there an award ceiling listed?

No award ceiling is specified in the provided source text. Applicants are directed to consult the full announcement package for budget limits and other details.

30) Where can applicants find the official pre-announcement reference?

The official pre-announcement reference is hosted by CDMRP at: https://cdmrp.health.mil/pubs/press/2026/vrppreann

31) What key details may require checking the full announcement package?

Based on the provided description, applicants may need to consult the full announcement package for budget limits, the period of performance, and other submission details not specified in the source text.